Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997017 · ClinicalTrials.gov registry record · Phase 2
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Phase 2 study of Cancer and Endometrial Cancer, sponsored by Aadi Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 9
- Study locations
NCT05997017 is a Phase 2 study of Cancer and Endometrial Cancer that is actively recruiting participants, run by Aadi Bioscience. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT05997017, a Phase 2 study of Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Aadi Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Conditions Studied
Interventions
- DRUG nab-sirolimus
Study Locations (9)
Arkansas
- Michael Birrer, MD, PhD - Little Rock
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Nevada
- Women's Cancer Center of Nevada - Las Vegas
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
Oklahoma
- Oklahoma University Stephenson Cancer Center - Oklahoma City
Rhode Island
- Women & Infants Hospital - Providence
Texas
- Texas Oncology - Tyler - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05997017
The ClinicalTrials.gov registry entry for NCT05997017 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT05997017 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arkansas, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT05997017 about?
NCT05997017 is a clinical study titled "Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer". A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
What is the current status of trial NCT05997017?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-12-28. Estimated completion is 2027-06.
What conditions does trial NCT05997017 study?
This clinical trial studies the following conditions: Cancer, Endometrial Cancer, Recurrent Endometrial Carcinoma, Tumor, Endometrioid Endometrial Cancer.
What interventions are being tested in trial NCT05997017?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT05997017?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997017 being conducted?
This trial has 9 study locations across Arkansas, Florida, Nevada, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.